COVAXX, a US company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers.

Find out what drove John McKearn, Ph.D. & CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-Cell leukemias and lymphomas, Acute Myeloid Leukemia, and Multiple Myeloma.